Savara, Inc. SVRA 深 沪
等待开盘 01-28 09:30:00 美东时间
5.85
+0.070
+1.21%
华盛通- 最 高5.95
- 今 开5.78
- 成交量 114.66万股
- 最 低 5.73
- 昨 收 5.78
- 总市值 10.12亿
- 52周最高 7.005
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 1.89
- 委 比 -95.12%
- 总股本 1.73亿
- 历史最高 17.187
- 量 比 0.90
- 振 幅 3.81%
- 历史最低 0.69
- 每 手 1
- 风险率 1.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Savara Enters New Material Definitive Agreement and Obligation
An update from Savara ( ($SVRA) ) is now available. Savara Inc., a Delaware cor...
01-27 21:43
Savara Strengthens Balance Sheet With Access To ~$150M in Non-Dilutive Capital To Support MOLBREEVI Launch
-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI --Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage
01-27 21:10
Savara Highlights Autoimmune PAP Burden in Updated Presentation
The latest announcement is out from Savara ( ($SVRA) ). In January 2026, Savara...
01-09 21:29
Savara And PANTHERx Rare Pharmacy Announce An Exclusive Distribution Agreement For MOLBREEVI
PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused
01-09 05:15
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Savara Resubmits MOLBREEVI BLA To FDA, With Fujifilm As Drug Substance Manufacturer
-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested --Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical
2025-12-22 21:38
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Wells Fargo Maintains Overweight on Savara, Raises Price Target to $9
Wells Fargo analyst Benjamin Burnett maintains Savara (NASDAQ:SVRA) with a Overweight and raises the price target from $7 to $9.
2025-12-18 22:54
European Patent Office Intends To Grant Savara Patent For Liquid Formulation Of MOLBREEVI
-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 ---- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI
2025-12-11 21:16
Savara Inc. ticks higher amid takeover speculation
Savara Inc. (SVRA) pared a loss and ticked higher by 0.2% amid takeover speculation. There's speculation that Savara may have attracted takeover interest, according to traders, who cited a Betaville ...
2025-12-03 03:39
